In additional analysis of specific pairs of mutations, patients with dominant TET2 followed by secondary SRSF2 mutations were significantly more likely to develop MDS/MPN that those with dominant SRSF2 followed by secondary TET2 mutations [OR 0.26 (0.12–0.62), P = .0013 vs. OR 0.84 (0.38–2.24), P = 0.7]. This evidence concerns the gene SRSF2 and myelodysplastic syndrome.